Curcumin and Resveratrol: Nutraceuticals with so Much Potential for Pseudoachondroplasia and Other ER-Stress Conditions

Round 1

Reviewer 1 Report

Dear Author,

this work resumes the potential effects of curcumin and resveratrol as natural antioxidant and antinflammatory drugs specifically for the pseudoachondroplasia condition. It represent a  summary and reflection on the possible integration of these nutraceuticals in the field of drugs with chondroprotective effects used to prevent and control this rare disease condition.

In my opinion, some minor revisions would be considered.

An update of cited references should be carried out.

Please, see the attached revised file.

With Best Regards, 

Comments for author File: Comments.zip

Author Response

Dear Reviewer 1:

Thank you for the thorough reading and suggestions.  Reference changes were made in lines 92, 94, 107, and 109 per your suggestion.  Additionally, a schematic showing the specific ER stress, inflammatory, oxidative and ERAD molecules that are normalized by curcumin and resveratrol treatment (Fig. 2). 

Reviewer 2 Report

In rows 31 and 37 there is extra space without needing it.

"Cartilage Oligomeric Matrix Protein (COMP)"-line 52, in my opinion, does not need to be underlined.

In my opinion you should abandon Figure 1 because most of it is repeated in Figure 2 and in the text you should refer to Figure 1A.

Figure 2B must be processed to be an original one in my opinion.

FDA (line 272) must appear in an explained manner when it appears for the first time in the text, namely in the introduction (line 42).

In my opinion, it is not necessary to add Table 1. the study carried out by you and published as another work is sufficiently explained in the text.

10.3-why is there no bibliography?

At the end of the work I would call the conclusions short and concise and then the perspectives

Author Response

Reviewer 2

Dear Reviewer 2:

Thank you for your helpful suggestions on the figures and tables and for catching errors.

In rows 31 and 37 there is extra space without needing it.

This mistake has been corrected.

"Cartilage Oligomeric Matrix Protein (COMP)"-line 52, in my opinion, does not need to be underlined.

            The underline has been omitted.

In my opinion you should abandon Figure 1 because most of it is repeated in Figure 2 and in the text you should refer to Figure 1A.

            Figure 1 was modified to reduce redundancy.

Figure 2B must be processed to be an original one in my opinion.

            This is a stand-alone figure now.

FDA (line 272) must appear in an explained manner when it appears for the first time in the text, namely in the introduction (line 42).

            This error has been corrected.

In my opinion, it is not necessary to add Table 1. the study carried out by you and published as another work is sufficiently explained in the text.

            Table 1 has been omitted.

10.3-why is there no bibliography?

            This oversight has been rectified.

At the end of the work, I would call the conclusions short and concise and then the perspectives

            The last part of the paper has been revised to address this concern.